Director/PDMR Shareholding – Replacement

Apr 7, 2009

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

HomeRNS NewsDirector ShareholdingDirector/PDMR Shareholding – Replacement
RNS Number : 2571Q
Advanced Medical Solutions Grp PLC
07 April 2009
 



For immediate release

7 April 2009

The Company announced on 3 April 2009 (RNS no. 1367Q) that following a share transaction, Dr Geoffrey Vernon, Non-executive Chairman of AMS, is beneficially interested in 960,000 ordinary shares of AMS. This should have read that Dr Vernon is beneficially interested in 1,000,000 ordinary shares of AMS.

The revised announcement is printed below in full.

Advanced Medical Solutions Group plc (“AMS” or the “Company”)

PDMR Shareholding

The Company has been notified that on 3 April 2009, Mrs Julie Vernon sold 33,000 ordinary shares of the Company at a price of 35.90 pence per share. On the same day, Dr Geoffrey Vernon, Non-executive Chairman of AMS, bought 33,000 ordinary shares of the Company at a price of 36.38 pence per share.

As a result of these transactions there has been no change to the beneficial interest of Dr Vernon and his connected parties in the ordinary shares of AMS, which remains at 1,000,000 ordinary shares equating to 0.70 per cent. of the issued share capital of the Company.

For further enquiries, please contact:

Advanced Medical Solutions Group plc

Mary Tavener, Finance Director        +44 (0) 1606 545 235

Investec Bank plc

Daniel Adams                                     +44 (0) 207 597 5970 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RDSIRMPTMMJMMIL

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.